Evidence map›Paper›PMID 42839071›Full record

ArticleLeukemia2026

Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.

Samuli Eldfors, Sumit Rai, Vineet Sharma, Tareq Hossan, Claudia Cabrera Pastrana, Amy Bertino, Angelique Gilbert, Sridhar Nonavinkere Srivatsan, Kimmo Porkka, Matthew J Walter and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Samuli Eldfors *Center for Cancer Research, Massachusetts General Hospital Cancer Center, Charlestown, MA, USA.ORCID http://orcid.org/0000-0001-5056-4750
Sumit Rai *Mass General Brigham Cancer Institute, Boston, MA, USA.
Vineet SharmaMass General Brigham Cancer Institute, Boston, MA, USA.
Tareq HossanDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Claudia Cabrera PastranaDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Amy BertinoMass General Brigham Cancer Institute, Boston, MA, USA.
Angelique GilbertMass General Brigham Cancer Institute, Boston, MA, USA.
Sridhar Nonavinkere SrivatsanDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0001-6293-4632
Kimmo PorkkaDepartment of Medicine, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0003-4112-5902
Matthew J WalterDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-7753-1091
Timothy A GraubertMass General Brigham Cancer Institute, Boston, MA, USA. tgraubert@mgb.org.

Funding

Targeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI Daniel C Link · 2013 to 2026
$31.6M
Academy of Finland (Suomen Akatemia) 334273U.S. Department of Health & Human Services | National Institutes of Health (NIH) P50CA171963
6 · The paper itself

Abstract

SRSF2 mutations occur in 5-15% of acute myeloid leukemia (AML) and ~15% of myelodysplastic neoplasms (MDS), are enriched in elderly/secondary AML, and lack mutation-directed therapy. We aimed to identify vulnerabilities in MDS/AML with SRSF2 mutations. Ex vivo drug-sensitivity testing of bone marrow cells from AML patients and controls showed that SRSF2-mutant cells are sensitive to CHK1 and WEE1 inhibitors. To test causality, we engineered isogenic K562 cell line clones expressing SRSF2

Identifiers

PMID42839071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.